2023
Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic
Rios-Hoyo A, Arriola E. Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic. Frontiers In Immunology 2023, 14: 1221097. PMID: 37876939, PMCID: PMC10590916, DOI: 10.3389/fimmu.2023.1221097.Peer-Reviewed Original ResearchConceptsBrain metastasesCell lung cancerLung cancerTumor cellsTreatment strategiesAnti-CTLA-4 antibodyManagement of brain metastasesPD-1/PD-L1 axisNon-small cell lung cancerSmall cell lung cancerBrain parenchymaEra of immunotherapyIntracranial malignant neoplasmsSequence of immunotherapySymptomatic brain metastasesImmune checkpoint inhibitorsPD-1/PD-L1Extravasation of tumor cellsTreatment of BMBlood-brain barrierCheckpoint inhibitorsDismal prognosisImmune cellsLocal invasionProtumor effects
2022
Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
Ríos-Hoyo A, Moliner L, Arriola E. Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge. Cancers 2022, 14: 1931. PMID: 35454838, PMCID: PMC9027936, DOI: 10.3390/cancers14081931.Peer-Reviewed Original ResearchMechanisms of resistanceNon-small cell lung cancerEGFR-mutant tumorsPercentage of non-small cell lung cancerCell lung cancerMultiple mechanisms of resistanceEGFR tumorsPotential therapeutic strategyClinical benefitToxicity profileTreatment optionsLung cancerFrequent alterationsTherapeutic strategiesAcquired mechanismsOsimertinibTumorMultiple mechanismsTreatmentEGFRIncreased useCancer91P Preexisting tumor host immunity delineates clinical outcomes in resectable non-small cell lung cancer
Rocha P, Rodrigo M, Moliner L, Ríos-Hoyo A, Masfarré L, Navarro-Gorro N, Menendez S, Taus A, Rodríguez A, Aguiló R, Belda J, Del Rey-Vergara R, Galindo M, Comerma L, Arriola E. 91P Preexisting tumor host immunity delineates clinical outcomes in resectable non-small cell lung cancer. Annals Of Oncology 2022, 33: s75. DOI: 10.1016/j.annonc.2022.02.101.Peer-Reviewed Original ResearchIncidence of complications associated to bile duct stents, in patients with advanced cancer: a single-center experience
Corbera A, Rios-Hoyo A, Visa L, Casadevall D, Ilzarbe L, Barranco L, Radosevic A, Servitja S. Incidence of complications associated to bile duct stents, in patients with advanced cancer: a single-center experience. Supportive Care In Cancer 2022, 30: 4373-4378. PMID: 35094137, DOI: 10.1007/s00520-021-06737-1.Peer-Reviewed Original ResearchConceptsBiliary stent placementBiliary tract carcinomaBile duct obstructionPlacement of self-expanding stentsEffective anti-cancer therapyECOG performance statusPatients not candidatesCohort of patientsBile duct stentingAnti-cancer therapySelf-expanding stentsInfectious complicationsOvarian cancerDuct stentingMalignant originMedian agePerformance statusClinicopathological characteristicsDuct obstructionStent placementMedian timeRetrospective studyClinical characteristicsOptimal treatmentLung cancer
2020
Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage
Conde-Estévez D, Monge-Escartín I, Ríos-Hoyo A, Monzonis X, Echeverría-Esnal D, Moliner L, Duran-Jordà X, Taus Á, Arriola E. Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage. Journal Of Chemotherapy 2020, 33: 32-39. PMID: 33267748, DOI: 10.1080/1120009x.2020.1849488.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAntineoplastic Agents, ImmunologicalBody Mass IndexCarcinoma, Non-Small-Cell LungFemaleHospitals, UniversityHumansImmune Checkpoint InhibitorsLung NeoplasmsMaleMiddle AgedPrognosisProgression-Free SurvivalProportional Hazards ModelsRetrospective StudiesSex FactorsSocioeconomic FactorsConceptsImmune-related adverse eventsImmune checkpoint inhibitorsNon-small-cell lung cancerAdverse eventsCharacteristics of immune-related adverse eventsDevelopment of immune-related adverse eventsNSCLC patients treated with immune checkpoint inhibitorsPatients treated with immune checkpoint inhibitorsImmune-related adverse events occurrenceTreated with immune checkpoint inhibitorsImmune checkpoint blockageTreated with nivolumabSecond-line settingThirty-one patientsAssociated with improved patient outcomesCheckpoint inhibitorsMedian OSPrognostic factorsImprove patient outcomesGrade 3Lung cancerPatientsPatient outcomesThirty-oneMonths